Prof. Bertrand Coiffier, perhaps the EU's foremost T-Cell Lymphpma specialist, briefly describes the results of an early trial in which Romidepsin (Istodax) was added to the standard CHOP regimen (Ro-CHOP) in previously untreated PTCL patients. This is perhaps the emergence of the long sought-after primary therapy for PTCL. From OncologyTube: http://www.oncologytube.com/v/103433...-lymphoma#link